|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2010-4-19
|
|
pubmed:abstractText |
This review of practice assessed all early breast cancer patients diagnosed over 12 months to determine the frequency of human epidermal growth factor receptor 2 (HER2) positivity and trastuzumab use. The frequency of HER2 positivity in routine practice (185/1319; 14%) was less than expected. A significant proportion of patients (56/185; 30%) did not receive trastuzumab, largely due to concerns about chemotherapy tolerability.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
1433-2981
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
Copyright 2010 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
22
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
289-93
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:20347281-Antibodies, Monoclonal,
pubmed-meshheading:20347281-Antibodies, Monoclonal, Humanized,
pubmed-meshheading:20347281-Antineoplastic Agents,
pubmed-meshheading:20347281-Breast Neoplasms,
pubmed-meshheading:20347281-Female,
pubmed-meshheading:20347281-Guideline Adherence,
pubmed-meshheading:20347281-Humans,
pubmed-meshheading:20347281-Receptor, erbB-2
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Review of testing and use of adjuvant trastuzumab across a cancer network--are we treating the right patients?
|
|
pubmed:affiliation |
Academic Unit of Clinical Oncology, Weston Park Hospital, Sheffield, UK.
|
|
pubmed:publicationType |
Journal Article,
Review
|
